Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers in this study are assessing the drug ACR-368 alone and in combination with increasing doses of low-dose gemcitabine in people with ovarian, endometrial, or urothelial (bladder) cancer that has come back despite prior treatment. ACR-368 works by stopping cancer cells from repairing damage to themselves and their DNA (genes). Gemcitabine damages the DNA inside cancer cells and prevents the cells from multiplying.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
V940 is made in a laboratory. It uses genes in your cancer to teach your immune system to fight the cancer. V940 is given as an injection into a muscle. Pembrolizumab boosts the ability of the immune system to find and kill cancer cells. It is given intravenously (by vein).
Researchers want to see if elacestrant alone or with abemaciclib works well against endometrial cancer. The people in this study have endometrial cancer that has spread or come back. Their cancers have a protein called the estrogen receptor (ER) and they have a normal version of the p53 gene. This gene stops cancer from growing.
Researchers want to see how well a new combination of drugs works to treat low-grade serous ovarian cancer. The drugs are avutometinib, defactinib, and letrozole. The people in this study have ovarian cancer that cannot be completely removed with surgery.
Researchers want to find the best dose of RMC-9805 to use in people with advanced solid tumors. The people in this study have cancer that keeps growing even with treatment. The tumors also have a mutation (change) in the KRAS gene called G12D.
The purpose of this study is to find the highest dose of the investigational drug RLY-2608 that can be used alone in people with advanced solid tumors and with fulvestrant in people with advanced breast cancer. Participants in this study will have cancers that contain a mutation in a gene called PIK3CA. Their cancers must have continued to grow despite treatment or be inoperable.
Researchers want to find the best dose of EVM14 when used alone or with pembrolizumab in people with solid tumors. The people in this study have a solid tumor that keeps growing after treatment and has spread. This study includes people with:
